Corey S. Goodman, Ph.D.

Chairman of the Board

Dr. Corey Goodman is a scientist, educator, entrepreneur, and venture capitalist.  He received his B.S. from Stanford University and his Ph.D. from U.C. Berkeley.  He was a Helen Hay Whitney postdoctoral fellow at U.C. San Diego.  He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at Berkeley (Dept. of Molecular and Cell Biology), where he was Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute.   He is currently Adjunct Professor of Neuroscience at U.C. Berkeley.  Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, Dawson Prize in Genetics, and Gruber Prize in Neuroscience.

Dr. Goodman moved from academia to biotechnology and pharma to help turn great science into impactful medicine for human health.  He has co-founded seven biotechnology companies (the first being Exelixis), and led one of them (Renovis) as President and CEO from a private to public company until its acquisition.  He was recruited to be President and founder of Pfizer’s Biotherapeutics and Bioinnovation Center and a member of Pfizer’s executive leadership team.

Today Dr. Goodman is a Managing Partner of venBio Partners, a venture capital firm he co-founded that focuses on innovative therapeutics for major unmet medical needs. In addition to FogPharma, he is Chair of the Board of Second Genome, ALX Oncology, Tallac, Axonis, and Attralus.  He is a member of the Board of NFlection.  He chaired Labrys Biologics, a company he founded, until its acquisition by Teva.  The Labrys drug, now called Ajovy, is a CGRP antibody for chronic migraine that was approved by the FDA in 2018.  venBio, launched in 2011, already has three approved drugs.

Dr. Goodman is former Chair of the California Council on Science and Technology (advising the Governor and State Legislature), a member of the University of California Innovation Council (advising the UC President), a member of the board of the Pacific Institute, former Chair of the National Research Council’s (NAS) Board on Life Sciences (advising the Federal Government), and past President of the McKnight Endowment Fund for Neuroscience. He advises numerous non-profits and foundations.